Plague vaccines: new developments in an ongoing search
Autor: | Ashok K. Chopra, Emily K. Hendrix, Jason A. Rosenzweig |
---|---|
Rok vydání: | 2021 |
Předmět: |
China
Economic growth 2019-20 coronavirus outbreak Yersinia pestis Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Disease Vaccines Attenuated Live attenuated Plague (disease) Applied Microbiology and Biotechnology DNA vaccines 03 medical and health sciences Pandemic Animals Humans 030304 developmental biology Plague Plague Vaccine 0303 health sciences Protection biology SARS-CoV-2 030306 microbiology COVID-19 Humoral Outbreak General Medicine Mini-Review biology.organism_classification Antibodies Bacterial Geography Protein subunit Plague vaccine Biotechnology |
Zdroj: | Applied Microbiology and Biotechnology |
ISSN: | 1432-0614 0175-7598 |
DOI: | 10.1007/s00253-021-11389-6 |
Popis: | As the reality of pandemic threats challenges humanity, exemplified during the ongoing SARS-CoV-2 infections, the development of vaccines targeting these etiological agents of disease has become increasingly critical. Of paramount concern are novel and reemerging pathogens that could trigger such events, including the plague bacterium Yersinia pestis. Y. pestis is responsible for more human deaths than any other known pathogen and exists globally in endemic regions of the world, including the four corners region and Northern California in the USA. Recent cases have been scattered throughout the world, including China and the USA, with serious outbreaks in Madagascar during 2008, 2013–2014, and, most recently, 2017–2018. This review will focus on recent advances in plague vaccine development, a seemingly necessary endeavor, as there is no Food and Drug Administration–licensed vaccine available for human distribution in western nations, and that antibiotic-resistant strains are recovered clinically or intentionally developed. Progress and recent development involving subunit, live-attenuated, and nucleic acid–based plague vaccine candidates will be discussed in this review. Key points • Plague vaccine development remains elusive yet critical. • DNA, animal, and live-attenuated vaccine candidates gain traction. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |